Susan G. Komen, the world’s leading breast cancer organization, announced research funding of $30.7 million for 98 research grants, with a focus on new treatments and understanding of the most lethal forms and stages of breast cancer. Komen funding to institutions in 27 states and 7 countries also includes research into new screening technologies, treatments for metastatic and aggressive types of breast cancer and disparities in breast cancer outcomes.
The grants include $300,000 in new funding for research at the University of Kansas Cancer Center, bringing Komen’s total research investment in Kansas to more than $10.5 million since 1982.
Metastatic breast cancer – which is breast cancer that has spread to other parts of the body like the brain, liver, bones or lungs – is responsible for almost all of the nation’s 40,000 annual breast cancer deaths. More than 154,000 women are living with metastatic disease in the U.S. today. By targeting metastatic disease, Komen is hoping to reduce breast cancer deaths dramatically in the U.S. “This focus on aggressive and metastatic disease is the foundation of our Bold Goal to reduce U.S. breast cancer deaths by 50% by 2026,” said Ellen Willmott, interim president and CEO of Susan G. Komen.
For more information, visit komenkansascity.org, behindtheribbon.org or call 816-842-0410.